IL18 and macrophage activation syndrome: IL-18 inhibition has demonstrated therapeutic benefits in preclinical models of various inflammatory diseases, and its role has been implicated in several human conditions, including myocardial pathology, metabolic syndrome, inflammatory bowel disease, and macrophage activation syndrome [13, 162].